FDA Grants Accelerated Approval to the Combination of Avutometinib and Defactinib for KRAS-mutated Recurrent Low-Grade Serous Ovarian Cancer By Ogkologos - May 30, 2025 808 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the RAMP-201 study Source RELATED ARTICLESMORE FROM AUTHOR Belzutifan Plus Lenvatinib Improves Outcomes Over Cabozantinib in Patients with Advanced RCC Following Progression to PD1 or PD-L1 Inhibitors Combining 177Lu-PSMA-617 with ADT Plus ARPI Prolongs rPFS in Patients with PSMA-positive Metastatic Androgen Pathway Modulator-Naive/Sensitive Prostate Cancer EMA Recommends Extension of Therapeutic Indications for Cetuximab MOST POPULAR Lisocabtagene Maraleucel Shows Deep, Durable Responses in Patients with Relapsed or... February 19, 2026 Marshall University Study Finds That Walnuts Suppress Breast Cancer Growth And... April 16, 2019 Mom’s Early-Stage Breast Cancer Discovered When She Undergoes Testing to Donate... August 21, 2019 New Research in Treating Non-Hodgkin Lymphoma and Predicting the Risk of... January 26, 2023 Load more HOT NEWS Survivors of Childhood Cancer are at Excess Risk of Late Mortality... Higher Pregnancy Rates and No Impact on Prognosis with Embryo/Oocyte Cryopreservation... 7 Practical Tips for Taking Long-Term Medication EMA Recommends Extension of Indications for Talazoparib
